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O
steoporosis is a skeletal disorder
characterized by compromised
bone strength predisposing it to
increase risk of fracture, with bone
strength determined by both bone den-
sity and bone quality.1 Periodontitis is an
inflammatory disease usually leading to
bone loss. In periodontitis, there is an
increased turnover of alveolar bone al-
though there may be a dominance of
bone resorption over bone formation,
leading to alveolar bone loss and loss of
attachment.2 Based upon knowledge of
the etiology and the common risk factors
involved, some authors3-5 have studied
the association between both processes.
The majority of studies3-5 have shown
low bone mass to be independently asso-
ciated with loss of alveolar crestal height
and tooth loss. However, studies that focus
on the relation of clinical attachment loss
and osteoporosis are less consistent.3
Many factors have been identified which
contribute to bone mass loss, including
natural or surgically created menopause
at an early age.4 Increase in bone resorp-
tion due to gonadal reasons and accel-
erated bone loss in the first decade after
menopause appear to be the main path-
ogenic factors in women.5 Therefore, post-
menopausal women are one of the risk
groups for periodontitis and osteoporosis.
Biochemical methods of measuring
specific markers are used routinely to
provide information on bone resorption
and formation. While many substances
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are being investigated for their potential to aid in the
assessment and monitoring of tissue loss in periodon-
titis, few are so directly related to bone metabolism.
Osteocalcin, a 49 amino acid non-collagenous matrix
protein of calcified tissue, is synthesized by osteoblasts.
It has been postulated to have a role in both bone
resorption and mineralization,6 is currently described
as the most specific marker of osteoblast function,7
and has been identified as the current best marker in
plasma of spontaneous bone loss in untreated post-
menopausal women.8 The serum level of this protein
is considered to be a marker of bone formation9,10 and
is routinely assayed in investigation and monitoring of
metabolic bone disorders.7 Serum osteocalcin is pre-
sently considered a valid marker of bone turnover when
resorption and formation are coupled, and a specific
marker of bone formation when formation and resorp-
tion are uncoupled.11
Gingival crevicular fluid, which is an exudate that
can be harvested from the sulcus or periodontal pocket,
has been regarded as a promising medium for the
detection of periodontal disease activity.12,13 The major-
ity of new diagnostic tests for periodontal disease use
GCF.14,15 However, of the more than 50 different com-
ponents in GCF evaluated to date, the majority lack
specificity to alveolar bone destruction and essentially
constitute soft-tissue inflammatory events.16,17 Sev-
eral investigations on osteocalcin levels in GCF from
periodontal patients2,16,18-21 have been reported, sug-
gesting that osteocalcin levels in GCF may reflect
inflammation at diseased sites, and there has been inter-
est in osteocalcin as a potential marker of bone
turnover in periodontal disease.2,10,11 However, the role
of osteocalcin in periodontal disease progression is still
unclear.
The aim of the present study was to assess plasma,
saliva, and GCF levels of osteocalcin and correlate them
with periodontitis and osteoporosis.
MATERIALS AND METHODS
Study Population and Clinical Examination
For 3 years, all the postmenopausal women >35 years
old who were patients at our Dental School were
invited to participate in the study, and 73 patients were
recruited. Our protocol and consent forms were ap-
proved by the Committee of Ethics and Research of the
University of Seville Hospital Virgen Macarena. All the
women met the following inclusion criteria: at least
12 months since the last menstrual period; at least seven
teeth; no hormone therapy; no medical treatment influ-
encing bone metabolism; and no metabolic diseases.
General data were recorded: age, age at menopause,
years since menopause, and history of cigarette smok-
ing. One clinician examined all the patients, recording
the following measurements for all teeth: 1) O’Leary
plaque index;22 2) van der Velden bleeding on probing
(BOP) index;23 3) probing depth (PD), measured from
the gingival margin to the most apical penetration of the
probe; and 4) recession measured from the cemento-
enamel junction to the gingival margin. Clinical attach-
ment level (CAL) was calculated by adding recession
to PD. PD and CAL were assessed at six sites per tooth:
mesial edge, midtooth, and distal edge on both facial
and lingual sides. According to the criteria established
by Machtei et al.,24 the clinical entity of periodontitis
is based on the presence of CAL ≥6 mm in two or more
teeth and one or more sites with PD ≥5 mm.
Sample Collection and Analytical Determinations
Blood was centrifuged to obtain plasma. GCF sam-
pling was performed based on the method previously
described by Nomura et al.25 Each patient was moni-
tored at four sites in the upper incisor teeth. In the perio-
dontitis group the sites were always PD ≥5 mm. After
isolation from saliva, the area around each site sam-
pled was dried and supragingival plaque removed. GCF
was collected for 2 minutes using four strips (20 ×
4 mm) of paper.§ Each strip was placed gently into
the gingival crevice until slight resistance was felt, and
GCF volume was collected. The GCF absorbed (µl)/
wet area (mm2) in the strip paper was calculated by
comparing it to the amount of a standard plasma con-
taining a low concentration of 125 I used as a tracer
that the strip can absorb, similar to what has been
described for blood specimens.26,27 A saliva sample
was also collected from the sublingual zone with the
same paper strips. The plasma, saliva, and GCF sam-
ples were placed in a microcentrifuge tube and vortexed
vigorously in 200 µl of extraction buffer consisting of
0.5 NaCl, 50 mM Tris-HCL (ph 7.4), 5 mM CaCl2, and
0.05% Brij 35 (polyoxyethylene23 lauryl ether) by a
modification of the method described by Lee et al.28
Osteocalcin Assay
Osteocalcin measurements in serum, saliva, and GCF
were made using an electrochemiluminescence tech-
nique.¶ Results were obtained from a calibration curve
performed in the system by means of a two-point cal-
ibration and a master curve included into the reactive
bar code. The linearity defined by the detection limit
and the calibration curve maximum concentration is
established in 0.500 to 300 ng/ml. The detection limit,
the lowest measurable osteocalcin concentration, is
calculated as the concentration situated two standard
deviations above the minor concentration calibrator
value of the master curve is 0.5 ng/ml. The minimum
volume used by the analyst to carry out a determina-
tion was 20 µl sample.
§ Whatmann Lab Sales Ltd., Maidstone, Kent, U.K.
 Nacalai Tesque Inc., Kyoto, Japan.
¶ Immulite 2000, Diagnostic Products Corporation, Los Angeles, CA.
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Table 1.
Clinical Characteristics by Periodontal
Disease Status (mean ± SD)
Non-Periodontitis Group Periodontitis Group
N women (%) 27 (37.0) 46 (63.0)
PD (mm) 2.0 ± 0.5 2.6 ± 0.7
CAL (mm) 2.1 ± 0.3 3.6 ± 1.1
BOP (%) 64.9 ± 18.3 74.5 ± 17.5
Plaque (%) 72.4 ± 25.8 67.5 ± 30.1
Table 2.
Periodontal Status in Relation With Bone
Mineral Density (mean ± SD)
NBG OEG OPG P
N women (%) 34 (46.6) 11 (15.1) 28 (38.4)
NPG (%) 14 (51.9) 2 (7.4) 11 (40.7)
PG (%) 20 (43.5) 9 (19.6) 17 (37.0) 0.36
PD (mm) 2.4 ± 0.5 2.6 ± 0.5 2.3 ± 0.5 0.24
CAL (mm) 2.9 ± 1.1 3.7 ± 1.6 3.0 ± 0.9 0.11
BOP (%) 65.6 ± 16.9 79.3 ± 18.4 74.3 ± 18.4 0.04
Plaque (%) 63.0 ± 32.6 59.0 ± 35.8 81.2 ± 12.5 0.01
Bone Mineral Density Measurements
Vertebral bone mineral density (BMD) was measured
in each woman by dual-energy x-ray absorptiometry.#
We used antero-posterior projections of L2-L4. BMD
was calculated as the average of density between L2
to L4, and expressed as g/cm2. The World Health Orga-
nization29 defines osteoporosis by a BMD measured
as two-and-one-half standard deviations (−2.5 SD)
below average peak bone density achieved in young
adults, matched by gender and race. Based on the val-
ues obtained, three groups were established: normal
healthy group (BMD ≥ −1 SD), osteopenic group (BMD
between < −1 SD and > −2.5 SD), and osteoporotic
group (BMD ≤ −2.5 SD).
Statistical Analysis
Data are expressed as mean ± standard deviation. Dif-
ferences between groups in normally continuous vari-
ables were assessed by analysis of variance (ANOVA),
using the Bonferroni test to establish differences
between groups. Discrete variables were analyzed by
means of frequency distribution. The comparative
analysis of discrete variables was carried out using the
chi-square test. Non-parametric Kruskal-Wallis test was
used to analyze non-normally distributed variables. The
Pearson correlation coefficient was used to analyze
correlation between variables. P <0.05 was considered
significant.
RESULTS
The mean age of the 73 women was 57.3 ± 7.7 years
(range 38 to 76 years). Only four were smokers, one
smoked >20 cigarettes/day and three <20 cigarettes/
day. Mean menopausal age was 48.1 ± 5.0 (range 38
to 60 years). Mean number of years since menopause
was 9.15 ± 7.5 (range 1 to 29 years).
According to the criteria established by Machtei
et al.,24 37.0% (N = 27) of the women were classified
without periodontitis (NPG) and 63.0% (N = 46) with
periodontal disease (PG) (Table 1). Mean PD, mean
CAL, and BOP were statistically higher in PG than in
the NPG group (P <0.05). There were no significant
differences in the percentage of sites with plaque
between both groups (P = 0.48).
According to bone mineral density assessed by den-
sitometry, 34 women (46.6%) were classified in the
normal (healthy) bone group (NBG), 11 (15.1%) in
the osteopenic group (OEG), and 28 (38.4%) in the
osteoporotic group (OPG) (Table 2). There was no sig-
nificant difference between NPG and PG groups in the
distribution of women according to their densitomet-
ric results (P = 0.36). No statistically significant differ-
ences between groups were observed in probing depth
(P = 0.24) or in CAL (P = 0.11). Women in osteopenic
and osteoporotic groups showed more BOP than those
in the healthy bone group, but differences were not
statistically significant (P = 0.04; non-significant
Bonferroni test). On the contrary, the mean percentage
of sites with plaque in osteoporotic women (81.2% ±
12.5%) was significantly higher than that in the os-
teopenic and normal healthy bone groups (63.0% ±
32.6% and 59.0% ± 35.8%, respectively) (P = 0.01; with
significant differences between the normal healthy bone
group and osteoporotic group in Bonferroni test).
Mean osteocalcin concentrations in serum, saliva,
and GCF in correlation with periodontal status of the
women are shown in Table 3. Serum and saliva osteo-
calcin concentrations did not show statistical differ-
ences between the two groups (P >0.05). On the
contrary, GCF osteocalcin concentrations were signif-
icantly higher in the periodontally diseased group (35.0
± 30.3 ng/ml) than in the healthy group (18.1 ± 15.2
ng/ml) (P = 0.008).
Mean osteocalcin concentrations in serum, saliva,
and GCF correlated with bone mineral density are
# QDR 1000, Hologic Inc., Waltham, MA.
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Table 7.
Correlation Between Gingival Crevicular Fluid
Osteocalcin Concentrations (ng/ml) and
Periodontal Clinical Parameters (mean ± SD)
OC <12 OC 12-30 OC ≥30 P
PD (mm) 2.2 ± 0.3 2.4 ± 0.5 2.6 ± 0.5 0.003
CAL (mm) 2.7 ± 1.1 3.1 ± 1.1 3.4 ± 1.1 0.008
BOP (%) 63.8 ± 19.8 69.6 ± 16.1 78.0 ± 16.5 0.01
Plaque (%) 64.3 ± 30.9 72.7 ± 29.6 71.0 ± 26.0 0.57
Table 5.
Correlation Between Serum Osteocalcin
Concentrations and Periodontal Clinical
Parameters (mean ± SD)
Normal OC Increased OC P
PD (mm) 2.4 ± 0.5 2.5 ± 0.7 0.73
CAL (mm) 3.0 ± 1.0 3.5 ± 2.0 0.43
BOP (%) 69.0 ± 18.3 81.1 ± 16.0 0.21
Plaque (%) 70.4 ± 27.2 84.8 ± 30.7 0.73
Table 4.
Correlation Between Serum, Saliva, and
Gingival Crevicular Fluid Osteocalcin
Concentrations (ng/ml) and Bone Mineral
Density (mean ± SD)
Total NBG OEG OPG P
Serum OC 7.3 ± 3.6 7.1 ± 3.2 5.6 ± 3.4 8.2 ± 4.1 0.12
Saliva OC 5.4 ± 3.1 5.2 ± 3.9 5.7 ± 2.8 5.3 ± 2.2 0.88
GCF OC 27.5 ± 26.2 27.5 ± 24.7 43.5 ± 47.3 24.4 ± 15.9 0.13
Table 6.
Correlation Between Saliva Osteocalcin
Concentrations (ng/ml) and Periodontal
Clinical Parameters (mean ± SD)
OC <3 OC 3-7 OC >7 P
PD (mm) 2.3 ± 0.5 2.6 ± 0.5 2.3 ± 0.5 0.11
CAL (mm) 2.6 ± 0.7 3.5 ± 1.3 2.9 ± 1.0 0.01
BOP (%) 67.0 ± 18.0 75.2 ± 19.2 66.7 ± 16.5 0.19
Plaque (%) 68.8 ± 26.8 84.5 ± 32.6 73.3 ± 25.6 0.41
shown in Table 4. No statistically significant differences
between densitometric groups were observed (P >0.05).
Women were classified according to their serum
osteocalcin concentration into two groups: normal
osteocalcin concentration group (osteocalcin con-
centration between 3.5 to 10 ng/ml) and increased
osteocalcin concentration group (osteocalcin concen-
tration ≥10 ng/ml). The correlation between serum
osteocalcin concentrations and periodontal clinical
parameters was examined (Table 5). No statistically
significant differences were observed (P >0.05). Using
the Pearson lineal correlation test, serum osteocalcin
concentration did not correlate with any periodontal
clinical parameter.
To study the correlation between saliva osteocalcin
concentrations and periodontal clinical parameters,
women were classified according to their serum osteo-
calcin concentration in three groups: 1) osteocalcin
concentration <3 ng/ml; 2) osteocalcin concentration
ranging from 3 to 7 ng/ml; and 3) osteocalcin con-
centration >7 ng/ml (Table 6). No statistically signifi-
cant differences in probing depth, bleeding on probing,
or percentage of dental plaque between the three
groups were observed (P >0.05). On the contrary, there
were significant differences between the three groups
in clinical attachment loss (P = 0.01; with significant
differences between the group <3 OC and >7 OC in
Bonferroni test). Using the Pearson lineal correlation
test, saliva osteocalcin concentrations did not corre-
late with any periodontal clinical parameter.
To study the correlation between GCF osteocalcin
concentrations and periodontal clinical parameters,
women were classified in three groups according to
their GCF osteocalcin concentration: 1) osteocalcin
concentration <12 ng/ml; 2) osteocalcin concentration
ranging from 12 to 30 ng/ml; and 3) osteocalcin
concentration >30 ng/ml (Table 7). Mean probing depth
Table 3.
Correlations Between Serum, Saliva, and
Gingival Crevicular Fluid Osteocalcin
Concentrations (ng/ml) and Periodontal
Status (mean ± SD)
NPG PG P
Serum OC 8.1 ± 3.7 6.8 ± 3.6 0.18
Saliva OC 4.9 ± 3.1 5.5 ± 3.1 0.41
GCF OC 18.1 ± 15.2 35.0 ± 30.3 0.008
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correlated significantly with GCF osteocalcin concen-
trations (r = 0.35; P = 0.002). Women with low GCF
osteocalcin concentrations showed a significantly lesser
probing depth (2.2 ± 0.3 ng/ml) than those with higher
GCF osteocalcin concentrations (P = 0.03). Bonferroni
test also showed significant differences between the
group with 12 to 30 ng/ml and the group with >30
ng/ml. Mean CAL did not correlate with GCF osteo-
calcin concentrations (r = 0.18; P = 0.119) but CAL
was significantly higher in the group with >30 ng/ml
osteocalcin concentration (P = 0.08). Bleeding on prob-
ing percentage increased in correlation with GCF
osteocalcin concentration (r = 0.25; P = 0.02 Bonferroni
test showed statistical differences between the group
with <12 ng/ml GCF osteocalcin and the group with
>30 ng/ml) (P = 0.01). No statistically significant dif-
ferences in percentage of dental plaque between the
three groups were observed (P >0.05).
DISCUSSION
Osteocalcin levels in serum, saliva, and gingival crevi-
cular fluid were determined in the present cross-
sectional study. To our knowledge, this is the first study
to measure osteocalcin concentrations in these three
fluids in both healthy and periodontally diseased sub-
jects. We showed that OC in GCF correlated signifi-
cantly (P = 0.008) with the periodontal status of the
patients. Moreover, in the present study, OC in GCF
correlated significantly with probing depth, clinical
attachment level, and bleeding on probing, three main
clinical parameters of periodontal disease. Addition-
ally, saliva OC has been shown to correlate significantly
with clinical attachment level.
It is unclear where osteocalcin in GCF originates.
Some of this protein will be derived from circulating lev-
els. However, it is also possible that osteocalcin will be
produced locally, either alveolar bone is resorbed or
from active local osteoblast synthesis.2,30 The reser-
voir of osteocalcin locked into the alveolar bone and
released into the GCF by osteoblast activity will, most
likely, be correlated with the local osteoblast activity.
The localization of osteocalcin in the entire human
periodontium including gingiva, periodontal ligament,
cementum, and alveolar bone has been studied.31 The
authors demonstrated its presence within the alveolar
bone, cementum, and periodontal ligament and a high
expression of osteocalcin in periodontal ligament fibro-
blasts. Since osteocalcin may play important roles in
cementogenesis, osteoblast differentiation, and bone
mineralization, it may express hard tissue metabolism.
Furthermore, the finding of increased bone density in
osteocalcin null mutant mice32 implicates osteocalcin
as a potential inhibitor of bone formation.
GCF was thought to be an inflammatory exudate
capable of detecting episodes of periodontitis,16 but it
has not been determined whether GCF markers in
humans directly correlate with those at the underlying
bone. There are clear diagnostic advantages in iden-
tifying an unambiguous marker of periodontal disease.
We therefore investigated GCF osteocalcin levels as a
marker of periodontitis. Osteocalcin is a specific
osteoblast product and raised levels in adult perio-
dontitis may be related to the severity of breakdown
and/or repair of alveolar bone. During active bone
resorption, osteocalcin and osteocalcin fragments
are likely to be released from the extracellular matrix
into the GCF.33 The fact that bone remodeling occurs
simultaneously in multiple skeletal location is gener-
ally viewed as evidence that it is locally controlled,
through autocrine and/or paracrine mechanisms.30 So,
osteocalcin levels in GCF are more informative than
serum or saliva levels regarding bone turnover in the
periodontium.
In the present study, patients with the highest OC in
GCF had significantly more probing depth, clinical
attachment level, and bleeding on probing, all clinical
parameters that involve periodontal disease. Moreover,
periodontally diseased women showed 2-fold higher
OC in GCF than healthy women (P = 0.008). These
results agree with previous data reported by other
investigators who studied the relationship between
GCF osteocalcin levels and periodontal disease.10,18,19
Kunimatsu et al.18 reported a positive correlation
between GCF osteocalcin N-terminal peptide levels
and clinical parameters in a cross-sectional study of
14 patients with periodontitis and five with gingivitis.
Nakashima et al.19 reported that OC in GCF corre-
lated significantly with the gingival index, but not with
probing depth. A longitudinal study using an experi-
mental periodontitis model in beagle dogs10 reported
a strong correlation between GCF osteocalcin levels
and active bone turnover as assessed by bone-seeking
radiopharmaceutical uptake. The results of the present
study, together with those of previous studies,10,18,19
support the concept that OC in GCF can be used as
a marker of periodontal disease.
On the other hand, several studies have found that
OC in GCF did not correlate with periodontal sta-
tus.2,14,16,20,21 Treatment of adult periodontitis patients
with subantimicrobial doxycycline failed to reduce
GCF osteocalcin levels.16 A cross-sectional study of
20 periodontitis patients reported no differences in
GCF osteocalcin levels between deep and shallow sites
in the same patients.2 Moreover, in a longitudinal study
of untreated periodontitis patients with ≥1.5 mm attach-
ment loss during the monitoring period,20 GCF osteo-
calcin levels alone were unable to distinguish between
active and inactive sites. In another study, osteocalcin
levels in the GCF during orthodontic tooth movement
were highly variable between subjects and lacked
a consistent pattern related to the stages of tooth
movement.14 Recently, Wilson et al.21 did not detect
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osteocalcin in GCF in 14 subjects with untreated perio-
dontitis. Several studies2,16,20 were performed in perio-
dontally diseased patients and did not compare healthy
and diseased subjects, but compared osteocalcin lev-
els in diseased and healthy sites in patients with adult
periodontitis.
One study concluded that a potential role exists for
whole osteocalcin as a bone-specific marker of bone
turnover but not as a predictive indicator of periodon-
tal disease.11 However, the results of the present study
demonstrated that OC in GCF is 2-fold higher in post-
menopausal periodontally diseased women in com-
parison with healthy women, strongly suggesting that
osteocalcin levels in GCF can also be used as a marker
of periodontal status.
Osteocalcin is predominantly synthesized by osteo-
blasts and it plays an important role in both bone
resorption and mineralization.30 The serum levels of
this protein are considered to be a marker of bone
remodeling and are routinely assayed in the investi-
gation and monitoring of metabolic bone disorders,
especially in osteoporosis.7 Elevated serum osteocal-
cin levels have been shown in periods of rapid bone
turnover such as osteoporosis, multiple myeloma, and
fracture repair.34 However, in the present study no cor-
relation between serum, saliva, and gingival crevicu-
lar fluid osteocalcin concentrations and bone mineral
density assessed by densitometry was found. The find-
ing that serum OC did not correlate with bone mineral
density could be explained because of the age of the
study population (57.3 ± 7.7 years) and the relatively
high number of years that passed since menopause
(9.15 ± 7.5 years). In agreement with these results, a
previous report on elderly women has shown that val-
ues of serum total osteocalcin were similar among
patients with and without subsequent hip fracture.35
The utility of serum OC to predict osteoporosis in
women over 67 has been reported as limited.36
According to the study by Looker et al., biochemical
markers of bone remodeling are neither surrogates nor
substitutes for measurements of bone mineral density
in elderly women.37
In the present study no correlation between serum
OC and periodontal status was found. Osteocalcin is
produced by osteoblasts in bone remodeling sites and
only a small fraction is directly secreted to blood.38
Serum levels of osteocalcin are unlikely to generate
data that reflect periodontal disease, as circulating lev-
els reflect bone turnover in the whole skeleton and any
contribution from bone remodeling would be masked.11
In conclusion, the results of the present study,
together with previous reports,10,18,19 further support
the concept that osteocalcin levels in GCF are related
with the patient periodontal status. It could be deduced
that an inhibition of bone formation could take place,
and this would facilitate the periodontal bone resorp-
tion. Additional longitudinal studies may be warranted
to elucidate more fully the usefulness of osteocalcin as
a diagnostic aid of periodontal disease activity.
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